Moomoo AI 已提取核心訊息
Altamira Therapeutics Ltd., a biopharmaceutical company, filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on January 8, 2024. The Bermuda-based company, led by President Thomas Meyer, PhD, is preparing for the proposed sale of common shares to the public, which will commence as soon as practicable after the registration statement becomes effective. The registration includes 162,548 common shares, which may be acquired upon the exercise of certain warrants issued in connection with a Warrant Inducement Agreement dated December 7, 2023. These warrants were issued to the holder on May 1, 2023, and additional warrants were provided on December 15, 2023, as an inducement for early exercise. The initial exercise price for the new warrants is set at CHF 6.656. Altamira Therapeutics will not receive...Show More
Altamira Therapeutics Ltd., a biopharmaceutical company, filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on January 8, 2024. The Bermuda-based company, led by President Thomas Meyer, PhD, is preparing for the proposed sale of common shares to the public, which will commence as soon as practicable after the registration statement becomes effective. The registration includes 162,548 common shares, which may be acquired upon the exercise of certain warrants issued in connection with a Warrant Inducement Agreement dated December 7, 2023. These warrants were issued to the holder on May 1, 2023, and additional warrants were provided on December 15, 2023, as an inducement for early exercise. The initial exercise price for the new warrants is set at CHF 6.656. Altamira Therapeutics will not receive any proceeds from the sale of shares by the selling shareholders, who will cover any underwriting discounts and commissions. The common shares are traded on the NASDAQ under the symbol 'CYTO', with the closing price on January 5, 2024, being $3.12 per share. The company has undergone several corporate actions, including reverse share splits and a change in the currency denomination of its authorized share capital.
生物製藥公司Altamira Therapeutics Ltd. 於2024年1月8日向美國證券交易委員會（SEC）提交了註冊聲明。這家總部位於百慕大的公司由總裁托馬斯·邁耶博士領導，正在爲擬議的向公衆出售普通股做準備，該計劃將在註冊聲明生效後儘快開始。註冊包括162,548股普通股，這些普通股可以在行使與2023年12月7日認股權證激勵協議相關的某些認股權證時收購。這些認股權證於2023年5月1日發行給持有人，並於2023年12月15日提供了額外的認股權證，以此作爲提前行使的誘因。新認股權證的初始行使價定爲6.656瑞士法郎。Altamira Therapeutics不會從出售股票的股東中獲得任何收益，股東將支付任何承保折扣和佣金。普通股在納斯達克上市，股票代碼爲 “CYTO”，2024年1月5日的收盤價爲每股3.12美元。該公司已採取多項公司行動，包括反向股份拆分和更改其法定股本的貨幣面值。
生物製藥公司Altamira Therapeutics Ltd. 於2024年1月8日向美國證券交易委員會（SEC）提交了註冊聲明。這家總部位於百慕大的公司由總裁托馬斯·邁耶博士領導，正在爲擬議的向公衆出售普通股做準備，該計劃將在註冊聲明生效後儘快開始。註冊包括162,548股普通股，這些普通股可以在行使與2023年12月7日認股權證激勵協議相關的某些認股權證時收購。這些認股權證於2023年5月1日發行給持有人，並於2023年12月15日提供了額外的認股權證，以此作爲提前行使的誘因。新認股權證的初始行使價定爲6.656瑞士法郎。Altamira Therapeutics不會從出售股票的股東中獲得任何收益，股東將支付任何承保折扣和佣金。普通股在納斯達克上市，股票代碼爲 “CYTO”，2024年1月5日的收盤價爲每股3.12美元。該公司已採取多項公司行動，包括反向股份拆分和更改其法定股本的貨幣面值。
有用
沒用